Myriad to Acquire Assurex Health for Up to $410M

Myriad Genetics has agreed to acquire Assurex Health for up to $410 million, in a deal that expands the buyer into genetic testing for psychotropic medicine selection. The deal, disclosed yesterday, gives Myriad its first commercial neuroscience diagnostic test, GeneSight®, whose potential market according to the company exceeds $4 billion based upon current and future indications. “This acquisition provides an experienced commercial organization in the neuroscience market that we believe will be one of the highest growth areas for personalized medicine and completes our infrastructure expansion consistent with our four-in-six strategy,” Myriad President and CEO Mark C. Capone said in a statement. “Four-in-six” is Myriad’s mission of answering patients’ four most pressing questions—Will I get a disease? Do I have a disease? Should I treat this disease? How should I…